Press "Enter" to skip to content

AstraZeneca-Merck’s Lynparza gets FDA okay to treat pancreatic cancer

The U.S. Food and Drug Administration (FDA) approved the drug’s use as a first-line maintenance therapy for patients with BRCA gene mutations whose cancer had spread beyond the pancreas and whose tumours did not worsen after chemotherapy of at least 16 weeks, the British drugmaker said on Monday.

Original source: